GREENLAND MINES LTD Increase (Decrease) in Accounts Payable
GREENLAND MINES LTD (GRML) reported Increase (Decrease) in Accounts Payable of $653.61 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-17
- GREENLAND MINES LTD increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $547.10K.
- GREENLAND MINES LTD increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $106.50K, a 3620.05% increase year-over-year.
- GREENLAND MINES LTD increase (decrease) in accounts payable for the quarter ending 2025-06-30 was -$53.92K.
- GREENLAND MINES LTD increase (decrease) in accounts payable for the quarter ending 2025-03-31 was $2.86K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month |
|---|---|---|
| 2026-06-30 | $547.10K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-17 | $653.61K 10-Q · filed 2026-08-17 |
| 2026-03-31 | $106.50K 10-Q/A · filed 2026-08-14 | |
| 2025-06-30 | -$53.92K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-17 | -$51.05K 10-Q · filed 2026-08-17 |
| 2025-03-31 | $2.86K 10-Q/A · filed 2026-08-14 | |
| 2024-06-30 | -$117.27K 10-Q · filed 2024-08-19 | |
| 2023-06-30 | $166.31K 10-Q · filed 2024-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |